glp 1 patients How young is too young for GLP-1s? Bariatric surgery? Academic experts offer insights NimbleRx I How to Talk

KLOW is not approved for human consumption but is sold for continuing research purposes

Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products

The meta-analysis found that several obesity medicines produce substantial and clinically meaningful weight loss, while #semaglutide and #tirzepatide showed important cardiovascular benefits in specific outcomes

The effects of weight loss-related amenorrhea on womens health and the therapeutic approaches: a narrative review

The most commonly reported side effects in non-diabetic users are gastrointestinalnausea, constipation, and occasional vomitingwhich typically diminish after the first 24 weeks as the body adjusts to the medication